mRNA-LNP Encapsulation Service

by | May 12, 2024

To ensure effective in vivo delivery, mRNA vaccines rely on not only optimized antigen sequences but also a robust delivery system capable of overcoming extracellular barriers, facilitating endosomal escape, and evading intracellular immune responses. Lipid...

Fluc-eGFP mRNA, Dual-Reporter for Protein Expression

by | Apr 25, 2024

In recent years, mRNA vaccines and drugs have received widespread attention around the world. Areterna LLC is proud to introduce Fluc-eGFP mRNA (Catalog number: 11013-CAP), a cutting-edge tool to accelerate your mRNA research. This mRNA encodes both eGFP and...

dsRNA: an unwanted byproduct from mRNA IVT

by | Apr 17, 2024

In vitro transcription (IVT) remains the predominant method for large-scale mRNA synthesis due to its efficiency and scalability. However, a significant challenge associated with IVT is the residual double-stranded RNA (dsRNA) produced as a by-product. This dsRNA can...

Why Co-Transcriptional Capping

by | Mar 25, 2024

In-vitro transcription (IVT) is a reactor-based scheme to manufacture RNA where cell-derived impurities or adventitious contaminants can be avoided thus making the manufacturing process GMP-friendly. The IVT reaction is often carried out at 37°C for 2...

Enzymatic Capping: Process, Pros, and Cons

by | Feb 20, 2024

We have discussed the evolution of cap analogs and the new generation of fine-tuned cap analogs for different applications. Generally, there are two ways of capping mRNA produced from an IVT reaction. One way is co-transcriptionally capping where a cap analog is added...